

In the claims:

Cancel claims 1-43, 48-50, 53-55, 58-59, 65, 67, 69, 71, 76, 78, and 83-91, without prejudice.

Amend claims 44, 63, 64, 66, 68, 70, 72, 73, 77, and 79-82 as follows.

44. (Amended) A cell [expressing a] which expresses at least two proteinaceous membrane-bound chimeric receptors,

the first of said receptors comprising (a) an extracellular portion which is capable of specifically recognizing and binding a target cell or a target infective agent, and (b) a transmembrane portion derived from a T cell receptor, a B cell receptor, or an Fc receptor which is capable of signalling said cell to destroy a receptor-bound target cell or a receptor-bound target infective agent; and

the second of said receptors comprising (a) an extracellular portion which is capable of specifically recognizing and binding said target cell or said target infective agent, and (b) an intracellular portion which is derived from CD28.

63. (Amended) The cell of claim[s 42 or] 47, wherein said Fc receptor protein is human FcγRIII, human FcRIIγA, or human FcRIIγC.

64. (Amended) The cell of claim[s 42 or] 47, wherein said T cell receptor protein

A3 is CD3 delta.

A4 66. (Amended) The cell of claim[s 42 or] 47, wherein said T cell receptor protein is T3 gamma.

A5 68. (Amended) The cell of claim[s 42 or] 47, wherein said B cell receptor protein is mb1.

A6 70. (Amended) The cell of claim[s 42 or] 47, wherein said B cell receptor protein is B29.

A7 72. (Amended) The cell of claim[s 39 or] 44, wherein said extracellular portion comprises the ligand-binding portion of a receptor, the receptor-binding portion of a ligand, the antigen-binding portion of an antibody, or a functional derivative thereof.

73. (Amended) The cell of claim[s 39 or] 44, wherein said target infective agent is an immunodeficiency virus or said target cell is a host cell infected with an immunodeficiency virus.

A4 77. (Amended) The cell of claim[s 39 or] 44, wherein said cell destroys said

Agonist
receptor-bound target cell or target infective agent by cytolysis.

79. (Amended) A cell which expresses [a] at least two proteinaceous membrane-bound chimeric receptors,

the first of said receptors comprising (a) an extracellular portion which is capable of specifically recognizing and binding a target cell or a target infective agent, and (b) a transmembrane portion derived from a T cell receptor CD3, zeta, or eta polypeptide, a B cell receptor, or an Fc receptor; and

the second of said receptors comprising (a) an extracellular portion which is capable of specifically recognizing and binding said target cell or said target infective agent, and (b) an intracellular portion which is derived from CD28.

80. (Amended) The cell of claim[s 78 or] 79, wherein said chimeric receptor includes a CD16 or CD5 extracellular portion.

81. (Amended) The cell of claim[s 78 or] 79, wherein said chimeric receptor includes a CD5 or CD7 transmembrane portion.

82. (Amended) The cell of claim[s 78 or] 79, wherein said chimeric receptor includes a CD5 or CD7 intracellular portion.

Add the following new claims 92-100.

--92. A cell which expresses a proteinaceous membrane-bound chimeric receptor, said receptor comprising (a) an extracellular portion which is capable of specifically recognizing and binding a target cell or a target infective agent, and (b) an intracellular portion derived from an Fc receptor FcγRIIIA γ, FcγRIIA, or FcγRIIC polypeptide which is capable of signalling said cell to destroy a receptor-bound target cell or receptor-bound target infective agent.

93. A cell which expresses a proteinaceous membrane-bound chimeric receptor, said receptor comprising (a) an extracellular portion which is capable of specifically recognizing and binding a target cell or a target infective agent, and (b) an intracellular portion derived from a B cell receptor mb1 polypeptide which is capable of signalling said cell to destroy a receptor-bound target cell or receptor-bound target infective agent.

94. The cell of claim 92 or 93, wherein said target cell is a host cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell.

95. The cell of claim 92 or 93, wherein said binding is MHC-independent.

96. The cell of claim 92 or 93, wherein said extracellular portion comprises the

ligand-binding portion of a receptor, the receptor-binding portion of a ligand, the antigen-binding portion of an antibody, or a functional derivative thereof.

97. The cell of claim 92 or 93, wherein said target infective agent is an immunodeficiency virus or said target cell is a host cell infected with an immunodeficiency virus.

98. The cell of claim 92 or 93, wherein said extracellular portion comprises an HIV envelope-binding portion of CD4, or a functional derivative thereof.

99. The cell of claim 98, wherein said HIV-envelope binding portion of CD4 comprises the peptide encoded by nucleotides 1-369 of SEQ ID NO:1.

100. The cell of claim 44, 92, or 93, wherein said cell destroys said receptor-bound target cell or target infective agent by cytolysis.--

REMARKS

Original claims 44-47, 51-52, 56-57, 60-64, 66, 68, 70, 72-75, 77, and 79-82, and new claims 92-100 are currently pending in this application.

Support for the amendments to the original claims is found in the claims.